# ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 16. august 2023	
Your name: Charlotte Näslund-Koch	
Manuscript title: Hvad betyder kost for psoriasis?	
Manuscript number (if known): UFL-06-23-0374	
,	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		

Click TAB in last row to add extra rows

		Click TAB III last row to add extra rows
Time frame: past 36 months		
2 Grants or contracts from	☐ None	
any entity (if not indicated in item #1 above).	Krista and Viggo Petersen's Foundation, The Danish National Psoriasis Foundation, The Kgl Hofbundtmager Aage Bang Foundation, Ellab Foundation, Herley	Payment made to my institution.

		and Gentofte Hospital	
		research fund, Siemens	
3	Royalties or licenses	None     Non	
		Z None	
4	Consulting fees	☑ None	
5	Payment or honoraria for		
3	lectures, presentations,	△ None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
,	D 16 1		
6	Payment for expert testimony		T
	testimony		
7	Support for attending	☐ None	
	meetings and/or travel	Leo Pharma	Travel expenses for attending EADV 2022
			Milano
8	Patents planned, issued or	⊠ None	
O	pending	M None	
	1 3		
_			
9	Participation on a Data	None     Non	
	Safety Monitoring Board or Advisory Board		
	or Advisory Board		
10	Leadership or fiduciary	None     Non	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
11	Stock or stock options	None     Non	
	, , , , , , , , , , , , , , , , , , ,	Z None	
10	Description of the second		1
12	Receipt of equipment, materials, drugs, medical		T
	writing, gifts or other		
	services		
13	Other financial or non-	□ None	
	financial interests	I have served as sub-	Payments to my institution.
		investigator in clinical	
		trials for Galderma,	
		Abbvie, LEO Pharma, Novartis, and CSL	
		Behring.	

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

### ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

<b>Date</b> : 16. august 2023
Your name: Niels Højsager Bennike
Manuscript title: Hvad betyder kost for psoriasis?
Manuscript number (if known): UFL-06-23-0374
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		

Click TAB in last row to add extra rows

Tim	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

#### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

# ICMJE DISCLOSURE FORM

Please save/export the filled in **form as PDF** before submitting it to Ugeskrift for Læger or Danish Medical Journal.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	ning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		

Click TAB in last row to add extra rows

Tim	e frame: past 36 months		
2	Grants or contracts from	□ None	
	any entity (if not indicated in item #1 above).	I have received research funding from Krista and Viggo Petersen's Foundation, Ellab Foundation, Novartis, Bristol-Myers Squibb, Janssen Pharmaceuticals, the	Payment to the hospital

		Danish National Psoriasis	
		Foundation, the LEO	
		Foundation, the Kgl	
		Hofbundtmager Aage	
		Bang Foundation,	
		Almirall and LEO	
		Pharma.	
3	Royalties or licenses	M None	
J	Royalties of licerises		
4	Consulting fees	☑ None	
5	Payment or honoraria for	□ None	
	lectures, presentations,	I have received	Payment made to me
	speakers bureaus,	honoraria as consultant	r ayment made to me
	manuscript writing or		
	educational events	and/or speaker for	
	educational events	AbbVie, Eli Lilly,	
		Novartis, Pfizer, and LEO	
		Pharma, Janssen Cilag,	
		UCB, Almirall, Bristol-	
		Myers Squibb, and	
		Sanofi.	
6	Payment for expert	⊠ None	
6	Payment for expert testimony	None	
6	Payment for expert testimony	None     Non	
6		⊠ None	
	testimony		
6	testimony  Support for attending		
	testimony		
	testimony  Support for attending		
7	Support for attending meetings and/or travel	None     Non	
	Support for attending meetings and/or travel  Patents planned, issued or		
7	Support for attending meetings and/or travel	None     Non	
7	Support for attending meetings and/or travel  Patents planned, issued or	None     Non	
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending	None     None     None     None	
7	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data	None     None     None     None	
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None None None I have participated in	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data	None None None I have participated in advisor board for	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None None None I have participated in	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi,	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag,	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen,	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS,	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS, Galderma and LEO	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS,	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS, Galderma and LEO	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS, Galderma and LEO	Payment made to me
7 8 9	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board or Advisory Board	None  None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS, Galderma and LEO Pharma.	Payment made to me
7 8	Support for attending meetings and/or travel  Patents planned, issued or pending  Participation on a Data Safety Monitoring Board	None  None  I have participated in advisor board for AbbVie, Pfizer, Sanofi, Janssen Cilag, Boehringer Ingelheim, Eli Lilly, Novartis, Janssen, Novo, UCB, BMS, Galderma and LEO	Payment made to me

	society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None     Non		
13	Other financial or non-financial interests	□ None		
		I have served as an	Payment made to the hospital	
		investigator for AbbVie,		
		Pfizer, Sanofi, Janssen		
		Cilag, Boehringer		
		Ingelheim, AstraZeneca,		
		Eli Lilly, Novartis,		
		Regeneron, Galderma,		
		and LEO Pharma.		

Please place an "X" next to the following statement to indicate your agreement:

 $\boxtimes$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

### IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.